Prior to the definition change, virtually all idh mutant were proneural secondary GBM.
After the WHO definition change, none of the above are considered GBM. The change really occurred about a year ago, but it was formalized November 19 of this year.
Now, there is only idh wildtype primary GBM, and that falls into two sub-classifications of mesenchymal and classical. Those are then each split into the two subdivisions of methylated and unmethylated MGMT.
Essentially the world did an end around on GBM, and the remaining definition happens to fit the proposed method of action for DCVax-l.
I guess some bear could call the new GBM definition (Aka: idh wildtype) a subgroup, but they’d be wrong, wrong, wrong. The definitional change was external to the trial, so (probable) exclusion of idh mutant from the trial is not considered an internal bias.
Imo.
Market Data 
Markets 
AI
